Related Experiment Video
Updated: Aug 29, 2025
Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models
Published on: April 7, 2018
Pancreatic Cancer Detection on CT Scans with Deep Learning: A Nationwide Population-based Study
Po-Ting Chen1, Tinghui Wu1, Pochuan Wang1
1From the Department of Medical Imaging (P.T.C., K.L.L.) and Division of Gastroenterology and Hepatology, Department of Internal Medicine (M.S.W., W.C.L.), National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan; Institute of Applied Mathematical Sciences (T.W., D.C., W.W.) and Departments of Computer Science and Information Engineering (P.W.) and Internal Medicine, College of Medicine (M.S.W., W.C.L.), National Taiwan University, No. 1, Section 4, Roosevelt Rd, Taipei 10617, Taiwan; Department of Medical Imaging, National Taiwan University Cancer Center, Taipei, Taiwan (K.L.L.); NVIDIA, Bethesda, Md (H.R.R.); and National Health Insurance Administration, Ministry of Health and Welfare, Taipei, Taiwan (P.C.L.).
Abstract:
Background Approximately 40% of pancreatic tumors smaller than 2 cm are missed at abdominal CT. Purpose To develop and to validate a deep learning (DL)-based tool able to detect pancreatic cancer at CT. Materials and Methods Retrospectively collected contrast-enhanced CT studies in patients diagnosed with pancreatic cancer between January 2006 and July 2018 were compared with CT studies of individuals with a normal pancreas (control group) obtained between January 2004 and December 2019. An end-to-end tool comprising a segmentation convolutional neural network (CNN) and a classifier ensembling five CNNs was developed and validated in the internal test set and a nationwide real-world validation set. The sensitivities of the computer-aided detection (CAD) tool and radiologist interpretation were compared using the McNemar test. Results A total of 546 patients with pancreatic cancer (mean age, 65 years ± 12 [SD], 297 men) and 733 control subjects were randomly divided into training, validation, and test sets. In the internal test set, the DL tool achieved 89.9% (98 of 109; 95% CI: 82.7, 94.9) sensitivity and 95.9% (141 of 147; 95% CI: 91.3, 98.5) specificity (area under the receiver operating characteristic curve [AUC], 0.96; 95% CI: 0.94, 0.99), without a significant difference (P = .11) in sensitivity compared with the original radiologist report (96.1% [98 of 102]; 95% CI: 90.3, 98.9). In a test set of 1473 real-world CT studies (669 malignant, 804 control) from institutions throughout Taiwan, the DL tool distinguished between CT malignant and control studies with 89.7% (600 of 669; 95% CI: 87.1, 91.9) sensitivity and 92.8% specificity (746 of 804; 95% CI: 90.8, 94.5) (AUC, 0.95; 95% CI: 0.94, 0.96), with 74.7% (68 of 91; 95% CI: 64.5, 83.3) sensitivity for malignancies smaller than 2 cm. Conclusion The deep learning-based tool enabled accurate detection of pancreatic cancer on CT scans, with reasonable sensitivity for tumors smaller than 2 cm. © RSNA, 2022 Online supplemental material is available for this article. See also the editorial by Aisen and Rodrigues in this issue.
